Skip to content
  • Facebook
  • Twitter
  • Instagram
  • Email
NEWSX 360 : The Global News Platform

NEWSX 360 : The Global News Platform

News from across the Globe

  • Home
  • About Us
  • Terms & Conditions
  • Contact Us
  • Editor’s Note
  • Privacy Policy
  • Toggle search form
  • Empowering Youth: Divyansh Sengar’s Mission to Democratize Digital Marketing Skills News
  • Narayan Rathod: Forging a Path of Innovation and Social Impact in the Mobile Accessories Industry News
  • Poornima Yadav Shines as Mrs. India World 2024 First Runner- Up – A Journey of Strength and Determination News
  • Law Conclave: ‘Gita, Vedas, Puranas In Lady Justice Statue’s Hand Will Indianise Justice,’ Says Supreme Court Justice Pankaj Mittal India
  • Surat’s PARK360 successfully manages access control and authorisation duties at G20 Leaders’ Summit News
  • Technology Mogul Vimal Daga Supports Indian Government’s Cloud First Policy News
  • Vidhan Group by Ambitious farmer enters real estate to raise the bar for premium living in Banaras News
  • Successful Conclusion of Osho Celebrations of SOJAT Golden Bhavan in Mumbai News

Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg.

Posted on May 30, 2022 By No Comments on Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg.

Pharma Desk, India: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ivabradine Tablets, 5 mg and 7.5 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Corlanor Tablets, 5 mg and 7.5 mg, of Amgen Inc. (Amgen). Ivabradine Tablets are indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. Ivabradine Tablets are indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate. It may not be indicated for certain other uses due to unexpired exclusivities for the RLD for such uses. Ivabradine Tablets, 5 mg and 7.5 mg have an estimated market size of US$ 102 million for twelve months ending December 2021 according to IQVIA. Alembic has received a cumulative total of 164 ANDA approvals (140 final approvals and 24 tentative approvals) from USFDA.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients. Information about Alembic can be found at https://www.alembicpharmaceuticals.com/; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573)

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.

Related

Uncategorized

Post navigation

Previous Post: Vadodara based female entrepreneur launches India’s first eco friendly products e commerce portal zeroite.com
Next Post: Comprehensive Men’s Sexual Health Solutions Added to Buenafe Clinic

Related Posts

  • Sandvik completes the acquisition of Preziss, a solutions provider for aluminum and composite machining Uncategorized
  • Spoločnosť GameChange Solar prijíma objednávky na 200 MW systémy Genius Tracker™ pre Kolumbiu Uncategorized
  • NextMart, Inc. – Well Plugging Program Uncategorized
  • Molecule Announces Energy Risk Management Software for Growing Renewables Sector Uncategorized
  • Hydro One Second Quarter 2022 Results Release August 9, 2022 Before Markets Open Uncategorized
  • Ascend presenta nuevos materiales para vehículos eléctricos y baterías en Battery Show Europe Uncategorized

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Art of Living
  • Arts
  • Auto & Transportation
  • Automobile
  • Aviation
  • Banking
  • BCA ELECTIONS 2026
  • Bollywood
  • Brands
  • Business
  • Business Technology
  • Commodities
  • Economy
  • Education
  • Energy
  • Entertain­ment & Media
  • Entertainment
  • Entrepreneurs
  • Environment
  • Financial Services & Investing
  • Fitness
  • Gadgets
  • Health
  • Housing & Infrastructure
  • India
  • Information Technology
  • International
  • International Education
  • Investment
  • Lifestyle
  • Narendra Modi
  • News
  • People & Culture
  • Pharma
  • Policy & Public Interest
  • Politics
  • Sports
  • Stock Market
  • Tamilnadu
  • Technology
  • Telecom
  • The Multitaskers: A Series On Entrepreneurship with difference.
  • Travel
  • Uncategorized
  • UNICEF
  • Wellness
  • World News

Recent Posts

  • Cockroach Party to CEC: Quit in 48 Hours — or We Take the Fight Nationwide Over 13 Crore Deleted Voters
  • A Temple of Health and a ₹1-Lakh-Crore Bet: Bengal CM, Gautam Adani Break Ground on 2,000-Bed Arogya Mandir
  • Baroda’s Moliya Captains Rest of India U-23 for CK Nayudu Trophy Clash in Chennai
  • Modi’s Poll Chief Faces Mutiny From His Own Bench.
  • Pranav Amin Represents BCA at 95th BCCI AGM; Baroda Set to Host Major International Fixtures

Recent Comments

No comments to show.

Archives

  • September 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • October 2021
  • September 2021

  • Aayush Wellness Announces 2nd Interim Dividend Brands
  • Progress Alliance Celebrates 5,000+ Employees in 5+ Cities Brands
  • Kingston FURY Launches High Performance PCIe 5.0 NVMe SSD Brands
  • How a Delhi Dietitian Can Help Women Balance Their Hormones Naturally Through Diet Brands
  • 5 Key Features That Make the TCL Q6CS Series a Smart Choice Brands
  • Ready Mix Construction IPO To Open On 6th February, Sets Price Band At Rs 121 to Rs 123 Per Share Brands
  • Dr. Ambedkar’s Vision: A Blueprint for Equality, Justice, and Work-Life Balance in India: Bhagirathi Jena Brands
  • Alnaya CSP LLC Review: Investment, Contact Center and Real Estate Brands

Powered by PressBook News WordPress theme